Marc Bickle, Ph.D.
Max Planck Institute of Molecular Cell Biology and Genetics
Marc Bickle obtained his PhD at the Biozentrum of the University of Basel, Switzerland, in the laboratory of Prof. Michael N. Hall, studying the mode of action of the immunosuppressive drug Rapamycin using yeast as a model system. After receiving his degree, he went to the Laboratory of Molecular Biology in Cambridge, UK, to work in the laboratory of Prof. Jonathan Hodgkin to study the molecular mechanism underlying behavior using C. elegans as a model organism. He then left England for Lyon, France, where he participated in the creation of a Biotech company, Aptanomics SA. He headed the yeast and molecular biology groups and developed several yeast 2 hybrid screening methods to obtain peptide aptamers and small chemical compounds targeting protein-protein interactions. He then went to Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) in Dresden, Germany, where he headed a group developing live cell High Content Screening methodologies. Since early 2008, he heads the screening facility of the MPI-CBG (TDS) developing chemical genomic cellular assays using automated microscopy, image analysis and multi variate statistics. He is strongly involved in SLAS, being a member of the Europe Council, of the education committee and of the editorial board of JBS.